Show simple item record

dc.contributor.authorFørland, Marthe Gurine
dc.contributor.authorTysnes, Ole-Bjørn
dc.contributor.authorAarsland, Dag
dc.contributor.authorMaple-Grødem, Jodi
dc.contributor.authorPedersen, Kenn Freddy
dc.contributor.authorAlves, Guido Werner
dc.contributor.authorLange, Johannes
dc.identifier.citationFørland, M.G., Tysnes, O.B., Aarsland, D. (2019) The value of cerebrospinal fluid alpha-synuclein and the tau/alpha-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathology. European Journal of Neurology, 27(1), pp. 43-50 .nb_NO
dc.description.abstractBackground and purpose Parkinson's disease (PD), dementia with Lewy bodies (DLB) and Alzheimer's disease (AD) are three of the most common neurodegenerative disorders. Up to 20% of these patients have the wrong diagnosis, due to overlapping symptoms and shared pathologies. A cerebrospinal fluid (CSF) biomarker panel for AD is making its way into the clinic, but an equivalent panel for PD and DLB and for improved differential diagnoses is still lacking. Using well‐defined, community‐based cohorts and validated analytical methods, the diagnostic value of CSF total‐α‐synuclein (t‐α‐syn) alone and in combination with total tau (t‐tau) in newly diagnosed patients with PD, DLB and AD was determined. Methods Cerebrospinal fluid concentrations of t‐α‐syn were assessed using our validated in‐house enzyme‐linked immunosorbent assay in 78 PD patients, 20 AD patients, 19 DLB patients and 32 controls. t‐tau was measured using a commercial assay. Diagnostic performance was assessed by receiver operating characteristic curve analysis. Results Compared to controls (mean 517 pg/ml), significantly lower levels of CSF t‐α‐syn in patients with PD (434 pg/ml, 16% reduction, P = 0.036), DLB (398 pg/ml, 23% reduction, P = 0.009) and AD (383 pg/ml, 26% reduction, P = 0.014) were found. t‐α‐syn levels did not differ significantly between PD, DLB and AD. The t‐tau/t‐α‐syn ratio showed an improved performance compared to the single markers. Conclusion This is the first study to compare patients with PD, DLB and AD at the time of diagnosis. It was found that t‐α‐syn can contribute as a teammate with tau in a CSF biomarker panel for PD and DLB, and strengthen the existing biomarker panel for AD.nb_NO
dc.publisherJohn Wiley & Sons Ltd.nb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.subjectdemens med Lewy-legemernb_NO
dc.subjectnevrodegenerative sykdommernb_NO
dc.titleThe value of cerebrospinal fluid alpha-synuclein and the tau/alpha-synuclein ratio for diagnosis of neurodegenerative disorders with Lewy pathologynb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.rights.holder© 2019 The Authors.nb_NO
dc.subject.nsiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Neurology: 752nb_NO
dc.source.journalEuropean Journal of Neurologynb_NO
cristin.unitnameInstitutt for kjemi, biovitenskap og miljøteknologi

Files in this item


This item appears in the following Collection(s)

Show simple item record

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Except where otherwise noted, this item's license is described as Navngivelse-Ikkekommersiell 4.0 Internasjonal